New York State Common Retirement Fund Sells 41,251 Shares of Illumina, Inc. (NASDAQ:ILMN)

New York State Common Retirement Fund reduced its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 24.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 126,859 shares of the life sciences company's stock after selling 41,251 shares during the quarter. New York State Common Retirement Fund owned approximately 0.08% of Illumina worth $17,664,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Jennison Associates LLC acquired a new stake in Illumina in the 4th quarter worth approximately $24,566,000. Duality Advisers LP increased its position in Illumina by 152.5% in the 4th quarter. Duality Advisers LP now owns 21,651 shares of the life sciences company's stock worth $3,015,000 after buying an additional 13,076 shares during the period. North Star Asset Management Inc. increased its position in Illumina by 29.3% in the 4th quarter. North Star Asset Management Inc. now owns 37,449 shares of the life sciences company's stock worth $5,214,000 after buying an additional 8,486 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in Illumina by 1.7% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 14,073 shares of the life sciences company's stock worth $1,960,000 after buying an additional 239 shares during the period. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its position in Illumina by 41.2% in the 4th quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 32,768 shares of the life sciences company's stock worth $4,563,000 after buying an additional 9,557 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Up 2.0 %

Shares of ILMN traded up $2.45 during trading hours on Monday, hitting $124.73. 900,186 shares of the stock traded hands, compared to its average volume of 1,708,604. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $213.91. The firm has a market capitalization of $19.86 billion, a PE ratio of -16.93 and a beta of 1.19. The business has a fifty day moving average of $131.51 and a 200-day moving average of $127.24.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.13. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.14 earnings per share. Analysts expect that Illumina, Inc. will post 0.91 EPS for the current year.

Analyst Ratings Changes

ILMN has been the topic of a number of research reports. OTR Global restated a "mixed" rating on shares of Illumina in a research report on Wednesday, March 20th. TD Cowen cut Illumina from an "outperform" rating to a "market perform" rating and set a $144.00 price objective on the stock. in a research report on Thursday, January 4th. HSBC cut Illumina from a "buy" rating to a "hold" rating in a research report on Tuesday, January 16th. Royal Bank of Canada restated an "outperform" rating and set a $253.00 price objective on shares of Illumina in a research report on Tuesday, April 9th. Finally, Barclays boosted their price objective on Illumina from $85.00 to $100.00 and gave the company an "underweight" rating in a research report on Wednesday, April 10th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Illumina presently has a consensus rating of "Hold" and an average target price of $167.70.

Insider Activity at Illumina

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the stock in a transaction on Thursday, February 22nd. The stock was bought at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the acquisition, the chief executive officer now directly owns 14,861 shares of the company's stock, valued at $2,010,544.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.